ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,566.46
      1.12%
      US Tech 100
      19,255.20
      1.29%
      Dow Jones
      40,421.36
      0.33%
      Brent Oil
      81.525
      0.01%
      Bitcoin
      67,632.78
      0.04%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU

      6. Maat Pharma SA (MAAT) Quote

      Maat Pharma SA

      Maat Pharma SA (MAAT)

      Monash Absolute Active Trust
      7.40
      0.00
      (0.00%)
      Closed July 22 11:30AM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      7.40
      Bid
      7.34
      Ask
      7.40
      Volume
      226
      7.30 Day's Range 7.40
      4.50 52 Week Range 9.90
      Market Cap
      85.96M
      Previous Close
      7.40
      Open
      7.40
      Last Trade
      24
      @
      7.4
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      2,121
      Shares Outstanding
      11,616,199
      Dividend Yield
      -
      PE Ratio
      -4.36
      Earnings Per Share (EPS)
      -1.7
      Revenue
      2.23M
      Net Profit
      -19.72M

      About Maat Pharma SA

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.maatpharma.com
      Headquarters
      Lyon, Rhone, Fra
      Founded
      1970
      Maat Pharma SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker MAAT. The last closing price for Maat Pharma was 7.40 €. Over the last year, Maat Pharma shares have traded in a share price range of 4.50 € to 9.90 €.

      Maat Pharma currently has 11,616,199 shares outstanding. The market capitalization of Maat Pharma is 85.96 € million. Maat Pharma has a price to earnings ratio (PE ratio) of -4.36.

      MAAT Latest News

      More News

      MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

      Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a...

      July 05 2024
      Business Wire

      MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux

      Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

      July 05 2024
      Business Wire

      MaaT Pharma annonce le résultat positif du premier DSMB pour l'essai clinique de Phase 2 en cours évaluant MaaT033 pour les patients recevant une allo-GCSH

      Le DSMB (Data Safety and Monitoring Board), un comité d’experts indépendants, a recommandé que l'essai se poursuive comme prévu et sans modifications. MaaT033 a montré un profil de sécurité...

      July 02 2024
      Business Wire

      MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16

      Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

      June 25 2024
      Business Wire

      MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer

      Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

      June 24 2024
      Business Wire

      MaaT Pharma: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

      Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: MaaT Pharma (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé...

      June 10 2024
      Business Wire

      MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting

      Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

      May 29 2024
      Business Wire

      MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros

      Regulatory News: THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR...

      May 15 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.2-2.631578947377.67.67.36117.40192597DE
      40.57.246376811596.98.146.916937.69797637DE
      12-1.86-20.08639308869.269.66.5221217.85538368DE
      260.68.823529411766.89.96.5218148.15650518DE
      521.0215.9874608156.389.94.517377.33542634DE
      156-6.1-45.185185185213.514.44.513439.50717405DE
      260-6.1-45.185185185213.514.44.513439.50717405DE

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MIRAMIRA Pharmaceuticals Inc
      $ 5.01
      (627.35%)
      		158.07M
      CMAXCareMax Inc
      $ 5.19
      (228.48%)
      		102.64M
      NUKKNukkleus Inc
      $ 0.499
      (55.94%)
      		26.19M
      SNOASonoma Pharmaceuticals Inc
      $ 0.423
      (37.34%)
      		4.87M
      ONDSOndas Holdings Inc
      $ 1.1297
      (34.06%)
      		2.19M
      LGCBLinkage Global Inc
      $ 3.6601
      (-29.82%)
      		168k
      CGBSCrown LNG Holdings Ltd
      $ 0.9997
      (-29.10%)
      		3.38M
      SPECSpectaire Holdings Inc
      $ 0.3962
      (-24.53%)
      		1.87M
      GSUNGolden Sun Health Technology Group Ltd
      $ 5.13
      (-23.66%)
      		158.58k
      PSNLPersonalis Inc
      $ 2.9808
      (-22.58%)
      		3.1M
      NVDANVIDIA Corporation
      $ 123.54
      (4.76%)
      		238.89M
      SQQQProShares UltraPro Short QQQ
      $ 8.09
      (-4.37%)
      		183.49M
      MIRAMIRA Pharmaceuticals Inc
      $ 5.01
      (627.35%)
      		158.07M
      SERVServe Robotics Inc
      $ 8.73
      (15.63%)
      		151.5M
      NCPLNetcapital Inc
      $ 0.1118
      (7.50%)
      		124.27M

      Discussion

      View Full Feed
      patrik patrik 4 minutes ago
      W2R,
      But there are some here expecting any day kaboom! I’m looking
      at end of year or possibility early 2025
      Patrik
      KBLB
      Stinger2014 Stinger2014 5 minutes ago
      The good news, the MC can’t get much lower. I still believe the RS is already baked in.
      CGAC
      DesertDrifter DesertDrifter 6 minutes ago
      Yep. I was just thinking out loud. Still not a lot of official stuff coming out about the Ear of Trump episode. No legit medical release that mentions any stitches, grafts, etc. the photos of him golfing without bandage the day after with no visible wounds seems still curious.
      fuagf fuagf 6 minutes ago
      Yep. It's a must do now after you've thrown that gauntlet down. https://www.democraticunderground.com/emoticons/toast.gif
      LCJR LCJR 6 minutes ago
      Volume seems correct. Not sure about the individual trades though.

      LCJR
      AAGC
      somberfox somberfox 6 minutes ago
      All of that experience, and here we are at near trip 0s with millions in dilution, a deal with your biggest partner gone in the wind and a month behind on an audit of nothing.

      Hey, we're getting a watch though.
      RONN
      SSKILLZ1 SSKILLZ1 6 minutes ago
      SSKMP Managed Index (As Of 7/22/24)

      Daily Performance
      -0.08%

      YTD Performance
      +5.20%

      Overall Performance
      +494.90% (Including Options Trading +358.88%)
      ExtremelyBullishZig ExtremelyBullishZig 7 minutes ago
      Cool! So he can bring the drug to market then? Or is he just better at making the science work...I am trying to figure this one out. Steady told us that no one's opinion matters...
      AVXL
      ddls ddls 8 minutes ago
      Yes, let's get this-junk going, for the note-holders.

      https://www.otcmarkets.com/otcapi/company/financial-report/397773/content
      BIEL
      janice shell janice shell 8 minutes ago
      I've never even thought of making my own ketchup. And I've been eating Heinz all my life. I'm still alive. I don't use all that much of it, though. I use much more mayo.
      Ashley250nelson Ashley250nelson 8 minutes ago
      Trials starting next week!lfgo Jim saved us
      GSTC
      GMH* GMH* 8 minutes ago
      The company themselves said that the dropout rate will decline over time, so I am going from that, but they also said it was in-line with trials. Also, note that the 5% drop was, I assume, from patient health decline. There was also a statement in the same article that the manufacturing success ra
      IOVA
      bigstocksnbonds bigstocksnbonds 9 minutes ago
      YES SIR!!!!!
      MasterBlastr MasterBlastr 9 minutes ago
      Have to take advantage of the rules of the game, to make it fair.
      bigstocksnbonds bigstocksnbonds 9 minutes ago
      Awesome yes!!!!!
      Real McCoy Real McCoy 9 minutes ago
      If you are going to start the cycle by saying that some folks here are cruelly committed to not allowing complete lies and fantasies to sit unrefuted, I will gladly complete the cycle by noting you are also guilty of an equal committment to fight for the right to say you believe said lies and fantas
      Scott 75 Scott 75 10 minutes ago
      Hopefully not on a cold slab somewhere.
      UATG
      janice shell janice shell 10 minutes ago
      Bobo is just so breathtakingly stupid.
      BADALI BADALI 10 minutes ago
      I am watching this week and will add if goes Lower.
      HIRU
      _-Abe-_ _-Abe-_ 11 minutes ago
      Just remember. This company has a pile of back orders to fill and are now able to begin that process. I’m looking forward to Q4 numbers.
      EOSE
      Genz2 Genz2 12 minutes ago
      https://www.theregister.com/AMP/2024/07/22/windows_crowdstrike_kernel_eu/

      Why is Microsoft blaming the EU when it is apparent that they didn’t allow Wave on Windows 10 and 11? I think they allowed Crowdstrike on their platform because they knew that Clownstrike was inferior to Window
      moosedogger moosedogger 12 minutes ago
      "I won't sell for less than "60.00"

      Prove that you really missed me! I think you are not only FOS but also suffer from excrement of the 11th magnitude clogging what used to be your brain.

      You might be the saddest and mentally sickest creature on the iHub boards.
      AUPH
      irishintelligence irishintelligence 12 minutes ago
      Who knows - it obviously does not matter. Nothing is stopping him from continuing to develop property.


      http://cdn.ceo.ca.s3-us-west-2.amazonaws.com/1dr223l-Anatomy%20of%20a%20Basher%20-%20Do%20and%20Don%27t.pdf

      “Use 10% fact and 90% suggestion”

      Fa
      SPZI

      Your Recent History

      EU
      MAAT
      Maat Pharma
      TG
      MLU
      Manulife Financial
      NYSE
      FLT
      FleetCor Technologies
      Delayed Upgrade Clock